Gut Liver.
2016 Sep;10(5):659-660. 10.5009/gnl16359.
Helicobacter pylori Eradication Therapy, the Reasonable First Line Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Irrespective of Infection Status and Disease Stages
- Affiliations
-
- 1Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. adagio@catholic.ac.kr
- KMID: 2412059
- DOI: http://doi.org/10.5009/gnl16359
Abstract
- No abstract available.
MeSH Terms
-
Anti-Bacterial Agents/*therapeutic use
Gastric Mucosa/microbiology
Helicobacter Infections/complications/*drug therapy/microbiology
*Helicobacter pylori
Humans
Lymphoma, B-Cell, Marginal Zone/*drug therapy/microbiology/pathology
Neoadjuvant Therapy/methods
Neoplasm Staging
Remission Induction
Stomach Neoplasms/*drug therapy/microbiology/pathology
Anti-Bacterial Agents
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Helicobacter pylori-negative Gastric Mucosa-associated Lymphoid Tissue Lymphoma
- Gastric Mucosa-associated Lymphoid Tissue Lymphoma Based on Outcome of Domestic Treatment
- Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment
- A Polypoid Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach Treated with Endoscopic Polypectomy
- Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single-Center Experience
